RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2024

Nov 13, 2024

SEC Form 4/A — Form 4/A

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2024-02-09

Reporting Person: Shulman Joseph (Chief Technical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-09	Common Stock	M	65175	$21.38	Acquired	70415	Direct
2024-02-09	Common Stock	M	3985	$6.80	Acquired	74430	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-09	Stock Option (right to buy)	$21.38	M	65175	Disposed	2030-07-26	Common Stock (65175)	Direct
2024-02-09	Stock Option (right to buy)	$6.80	M	3985	Disposed	2022-02-08	Common Stock (3985)	Direct

Footnotes

F1: This amendment is being filed to correct the number of options exercised in row two of each of Table I and Table II in the originally filed Form 4 on February 13, 2024; and to report the exercise of the options in row two of each of Table I and Table II in this amended Form 4. The originally filed Form 4 reported 69,190 options exercised in row two of each of Table 1 and Table II which should have been 69,160, the total amount actually exercised.

F2: The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.

F3: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.